Filtered By:
Drug: Pravastatin

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 49 results found since Jan 2013.

Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: the Japan Statin Treatment Against Recurrent Stroke (J‐STARS)
ConclusionThis article reports the rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke. Follow‐ups of patients are in progress and will end in 2014.
Source: International Journal of Stroke - September 9, 2013 Category: Neurology Authors: Yoji Nagai, Tatsuo Kohriyama, Hideki Origasa, Kazuo Minematsu, Chiaki Yokota, Shinichiro Uchiyama, Setsuro Ibayashi, Yasuo Terayama, Makoto Takagi, Kazuo Kitagawa, Eiichi Nomura, Naohisa Hosomi, Toshiho Ohtsuki, Takemori Yamawaki, Yoshihiro Matsubara, Mas Tags: Research Source Type: research

Executive function, but not memory, associates with incident coronary heart disease and stroke
Conclusion: Lower executive function, but not memory, is associated with higher risk of coronary heart disease and stroke. Lower executive function, as an independent risk indicator, might better reflect brain vascular pathologies.
Source: Neurology - August 31, 2015 Category: Neurology Authors: Rostamian, S., van Buchem, M. A., Westendorp, R. G. J., Jukema, J. W., Mooijaart, S. P., Sabayan, B., de Craen, A. J. M. Tags: All Cerebrovascular disease/Stroke, Cardiac, Cognitive aging, Cohort studies, Risk factors in epidemiology ARTICLE Source Type: research

Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence Clinical Sciences
Conclusions—The composite risk of stroke and transient ischemic attack reduced in the postrandomized LDL cholesterol level of 80 to 100 mg/dL after adjusting for statin usage.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00221104.
Source: Stroke - March 26, 2018 Category: Neurology Authors: Naohisa Hosomi, Kazuo Kitagawa, Yoji Nagai, Yoko Nakagawa, Shiro Aoki, Tomohisa Nezu, Tatsuo Kagimura, Hirofumi Maruyama, Hideki Origasa, Kazuo Minematsu, Shinichiro Uchiyama, Masayasu Matsumoto Tags: Lipids and Cholesterol, Secondary Prevention, Treatment Original Contributions Source Type: research

Statin Therapy in Ischemic Stroke Models: A Meta-Analysis
AbstractStatins, drugs known for lipid lowering capabilities and reduction of cardiovascular disease, have demonstrated neuroprotective effects following ischemic stroke in retrospective clinical and animal studies. However, dosing (methods, time, type of statin, and quantity) varies across studies, limiting the clinical applicability of these findings. Furthermore, a comprehensive review of statins in edema and blood-brain barrier (BBB) breakdown is needed to provide insight on diverse, less explored neuroprotective effects. In the present study, we conduct a meta-analysis of publications evaluating statin administration ...
Source: Translational Stroke Research - December 1, 2019 Category: Neurology Source Type: research

Infratentorial Microbleeds: Another Sign of Microangiopathy in Migraine Brief Reports
Conclusions— Migraine, notably without aura, is associated with infratentorial CMBs at older age. CMBs and infarcts co-occur more often in migraine than in controls. This supports the hypothesis of small-vessel involvement in migraine pathophysiology.
Source: Stroke - June 22, 2015 Category: Neurology Authors: Arkink, E. B., Terwindt, G. M., de Craen, A. J. M., Konishi, J., van der Grond, J., van Buchem, M. A., Ferrari, M. D., Kruit, M. C., on behalf of the PROSPER Study Group Tags: Cerebrovascular disease/stroke, Computerized tomography and Magnetic Resonance Imaging, Risk Factors for Stroke Brief Reports Source Type: research

The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Echo Study: Rationale and Trial Protocol
The preventive effect of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) on progression of carotid intima-media complex thickness (IMT) has been shown exclusively in nonstroke Western patients. The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Echo Study aims to determine the effect of pravastatin on carotid IMT in Japanese patients with hyperlipidemia who developed noncardioembolic ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - December 20, 2016 Category: Neurology Authors: Kazunori Toyoda, Kazuo Minematsu, Masahiro Yasaka, Yoji Nagai, Naohisa Hosomi, Hideki Origasa, Kazuo Kitagawa, Shinichiro Uchiyama, Masatoshi Koga, Masayasu Matsumoto, J-STARS Investigators Source Type: research

Pravastatin Reduces the Risk of Atherothrombotic Stroke when Administered within Six Months of an Initial Stroke Event.
CONCLUSIONS: Pravastatin is likely to reduce atherothrombotic stroke in patients enrolled within 6 months after stroke onset. However, the clinical efficacy for prevention of recurrent stroke was not conclusive with earlier statin treatment. PMID: 28924103 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - September 20, 2017 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Reduction in High-Sensitivity C-Reactive Protein Levels in Patients with Ischemic Stroke by Statin Treatment: Hs-CRP Sub-Study in J-STARS.
CONCLUSION: In non-cardiogenic ischemic stroke, pravastatin treatment may reduce vascular inflammation as assessed by Hs-CRP, and higher Hs-CRP levels appeared to increase the risk of recurrent stroke and vascular events. PMID: 28302952 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - March 19, 2017 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) Decade?
We describe the current status of lipid-lowering therapies for ischemic stroke prevention. The SPARCL trial published in 2006 has been a landmark study in vascular neurology. The trial demonstrated that high-dose atorvastatin prevents recurrent stroke, and led the AHA/ASA to recommend statin therapy for patients with stroke or TIA of atherosclerotic origin.Recent findingsRecently, the J-STARS study demonstrated that therapy with low-dose pravastatin reduced atherothrombotic infarction incidence among patients with prior ischemic stroke. Besides, several trials have shown improved stroke outcomes with non-statin lipid-lower...
Source: Current Treatment Options in Neurology - April 7, 2019 Category: Neurology Source Type: research

Cumulative Effects of LDL Cholesterol and CRP Levels on Recurrent Stroke and TIA.
CONCLUSIONS: The control of both LDL cholesterol and CRP levels appears to be effective for preventing recurrent stroke and TIA in patients with non-cardiogenic ischemic stroke. PMID: 30318492 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - October 16, 2018 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Effect of Statin on Stroke Recurrence Prevention at Different Infarction Locations: A Post Hoc Analysis of The J-STARS Study.
CONCLUSIONS: Pravastatin significantly reduced the recurrence rate of all stroke among patients with PCS. Thus, the effect of statin on the recurrence of stroke may differ according to infarction location. PMID: 31554765 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - September 27, 2019 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Different Influences of Statin Treatment in Preventing At-Risk Stroke Subtypes: A Post Hoc Analysis of J-STARS.
CONCLUSIONS: Statins showed different influences on the risks of atherothromobotic and lacunar stroke according to postrandomized LDL cholesterol levels. PMID: 31534062 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - September 20, 2019 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus
AbstractPurpose of ReviewThe aim of this study is to investigate the protective effects of different statin classes, intensity, and cumulative dose-dependent against primary ischemic stroke in patients with T2DM.Recent FindingsThe Cox hazards model was used to evaluate statin use on primary ischemic stroke. Case group: T2DM patients who received statins; control group: T2DM patients who received no statins during the follow-up. Adjusted hazard ratio (aHR) for primary ischemic stroke was 0.45 (95% CI: 0.44 to 0.46). Cox regression analysis showed significant reductions in primary ischemic stroke incidence in users of differ...
Source: Current Atherosclerosis Reports - July 29, 2023 Category: Cardiology Source Type: research

Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study
ConclusionAmong patients treated with a statin following ischemic stroke, the risk of intracranial hemorrhage is not influenced by statin lipophilicity.
Source: Drug Safety - June 15, 2017 Category: Drugs & Pharmacology Source Type: research